Everett Harris & Co. CA Grows Stock Holdings in Henry Schein, Inc. (NASDAQ:HSIC)

Everett Harris & Co. CA grew its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 15.2% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 148,542 shares of the company’s stock after buying an additional 19,600 shares during the period. Everett Harris & Co. CA owned approximately 0.12% of Henry Schein worth $10,829,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. First Citizens Bank & Trust Co. increased its position in shares of Henry Schein by 49.3% during the 3rd quarter. First Citizens Bank & Trust Co. now owns 74,634 shares of the company’s stock valued at $5,441,000 after purchasing an additional 24,641 shares during the last quarter. Blue Trust Inc. raised its stake in shares of Henry Schein by 157.0% in the third quarter. Blue Trust Inc. now owns 2,393 shares of the company’s stock valued at $174,000 after acquiring an additional 1,462 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in shares of Henry Schein by 2.7% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 12,994 shares of the company’s stock worth $947,000 after acquiring an additional 340 shares during the last quarter. Marathon Asset Management Ltd boosted its stake in shares of Henry Schein by 3.2% during the 3rd quarter. Marathon Asset Management Ltd now owns 279,203 shares of the company’s stock worth $20,354,000 after purchasing an additional 8,742 shares during the period. Finally, Cardinal Capital Management grew its holdings in Henry Schein by 6.4% during the 3rd quarter. Cardinal Capital Management now owns 14,202 shares of the company’s stock valued at $1,035,000 after purchasing an additional 857 shares during the last quarter. 96.62% of the stock is currently owned by institutional investors.

Henry Schein Stock Up 1.0 %

Shares of HSIC traded up $0.72 during mid-day trading on Friday, hitting $72.39. The company’s stock had a trading volume of 688,164 shares, compared to its average volume of 1,335,087. The company has a current ratio of 1.55, a quick ratio of 0.90 and a debt-to-equity ratio of 0.46. The company’s 50-day moving average is $70.40 and its 200-day moving average is $69.90. Henry Schein, Inc. has a 52-week low of $60.01 and a 52-week high of $82.63. The firm has a market capitalization of $9.27 billion, a price-to-earnings ratio of 24.46, a PEG ratio of 1.98 and a beta of 0.86.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, August 6th. The company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.01. Henry Schein had a return on equity of 13.19% and a net margin of 2.82%. The business had revenue of $3.10 billion for the quarter, compared to analysts’ expectations of $3.27 billion. During the same quarter last year, the firm earned $1.31 EPS. The business’s revenue for the quarter was up .0% on a year-over-year basis. On average, equities research analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Insider Buying and Selling at Henry Schein

In other news, SVP Lorelei Mcglynn sold 21,035 shares of Henry Schein stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $69.30, for a total value of $1,457,725.50. Following the transaction, the senior vice president now owns 71,833 shares of the company’s stock, valued at $4,978,026.90. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.14% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on HSIC. Barrington Research reissued an “outperform” rating and issued a $82.00 price objective on shares of Henry Schein in a research note on Friday, September 20th. Piper Sandler restated an “overweight” rating and set a $86.00 price objective on shares of Henry Schein in a report on Friday, June 21st. Baird R W upgraded Henry Schein from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 22nd. JPMorgan Chase & Co. lowered their target price on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Finally, Robert W. Baird reduced their price target on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, six have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Henry Schein has an average rating of “Hold” and a consensus price target of $77.50.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.